Determining the specificity and biological functions of widespread host mRNA degradation by RNase L
确定 RNase L 广泛降解宿主 mRNA 的特异性和生物学功能
基本信息
- 批准号:9757551
- 负责人:
- 金额:$ 6.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-09 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:AffectAntiviral AgentsAntiviral resistanceApoptosisApoptoticAutoimmune DiseasesBioinformaticsBiologicalBiological ProcessCellsChronicConsensusDiseaseDouble-Stranded RNAElementsEndoribonucleasesFluorescent in Situ HybridizationGene ExpressionGenesGenetic TranscriptionGenetic TranslationGrantHigh-Throughput Nucleotide SequencingHigh-Throughput RNA SequencingInfectionInflammationInflammatoryInnate Immune ResponseInnate Immune SystemInterferon-betaInterferonsLeadMalignant NeoplasmsMammalian CellMediatingMessenger RNAModelingMolecularMultiple SclerosisMutagenesisNull LymphocytesPathway interactionsPatternPhosphorylationProductionProteinsResearchResistanceRheumatoid ArthritisRibonucleasesRibosomal RNARibosomesRoleSpecificityStressStructureSystemic Lupus ErythematosusTestingTranslatingTranslationsWorkbasechronic infectioncytokineexperimental studyhuman diseasehuman pathogenimmune system functioninnovationinsightmRNA DecaymRNA ExpressionmRNA Transcript Degradationnew technologynovelpathogenpromoterpseudotoxoplasmosis syndromeresponseribosome profilingsingle cell analysissingle molecule
项目摘要
Project Summary/Abstract
The innate immune response is crucial for controlling infection by human pathogens. However, over-activation
of the innate immune response can cause chronic inflammation that leads to human diseases, such as cancers
and autoimmune disorders. To better understand and treat these diseases, developing a deeper understanding
of how the innate immune system functions is paramount. In particular, the mechanisms that lead to global host
shut-off of translation in response to double-stranded RNA (dsRNA), while allowing the expression of dsRNA-
induced antiviral and pro-inflammatory mRNAs has remained an incompletely understood aspect of the innate
immune response.
Assessment of the potent antiviral endoribonuclease, ribonuclease L (RNase L), at the single-cell level revealed
that it is the primary driver of translational arrest and functions by promoting rapid and widespread turnover of
mRNAs. This is a significant shift in the understanding of dsRNA-induced translational arrest, as it would permit
translation of mRNAs that are not degraded by RNase L. Consistent with this, the mRNA of the potent antiviral
interferon-b (IFN-b) cytokine escapes RNase L-mediated mRNA turnover, potentially allowing for translation of
the IFN-b mRNA.
Based on these preliminary findings, this application proposes to test the hypothesis that widespread RNase L-
mediated mRNA turnover functions to preferentially promote translation of antiviral mRNAs that are resistant to
RNase L-mediated mRNA turnover. These findings may provide novel insights into RNase L-mediated
translational arrest and antiviral gene expression that will have translational importance for understanding and
treating human disease associated with dysregulation of the innate immune response. Aim 1: High-throughput
sequencing and single-molecule fluorescent in situ hybridization (smFISH) will be used to identify mRNAs in
addition to the IFN-b mRNA that are resistant to RNase L-mediated mRNA turnover. Aim 2: Targeted
mutagenesis, chimeric mRNAs, and heterologous promoters, will be used to determine the mechanistic basis by
which RNase L resistant mRNA escape RNase L-mediated mRNA turnover. Aim 3: Single-cell analysis of mRNA
expression and protein translation in conjunction with ribosomal profiling will be performed to determine if RNase
L-mediated mRNA promotes the translation of RNase L resistant mRNAs. Completion of these aims will
determine the breadth of mRNAs resistant to RNase L-driven mRNA turnover, determine the mechanism(s) by
which mRNAs escape RNase L-mediated mRNA turnover, and provide a novel mechanism by which RNase L
regulates antiviral gene expression during the innate immune response.
!
项目总结/摘要
先天免疫应答对于控制人类病原体的感染至关重要。然而,过度激活
先天免疫反应的一部分会引起慢性炎症,导致人类疾病,如癌症,
和自身免疫性疾病。为了更好地了解和治疗这些疾病,
先天免疫系统的功能至关重要。特别是,导致全球宿主的机制
响应于双链RNA(dsRNA)而关闭翻译,同时允许dsRNA的表达,
诱导的抗病毒和促炎基因仍然是一个不完全理解的方面的先天性
免疫反应
在单细胞水平上评估有效的抗病毒核糖核酸内切酶,核糖核酸酶L(RNase L),
它是翻译停滞的主要驱动力,并通过促进快速和广泛的周转来发挥作用。
mRNA。这是对dsRNA诱导的翻译停滞理解的一个重大转变,因为它允许
不被RNase L降解的mRNA的翻译。与此一致的是,有效抗病毒药物的mRNA
干扰素-b(IFN-b)细胞因子逃避RNase L介导的mRNA周转,可能允许翻译
IFN-b mRNA。
基于这些初步发现,本申请提出检验广泛存在的RNase L-
介导的mRNA周转功能,优先促进抗病毒mRNA的翻译,
RNA酶L介导的mRNA周转。这些发现可能为RNase L介导的
翻译停滞和抗病毒基因表达,这将对理解和
治疗与先天免疫应答失调相关的人类疾病。目标1:高通量
测序和单分子荧光原位杂交(smFISH)将用于鉴定
此外,IFN-b mRNA对RNase L介导的mRNA周转具有抗性。目标2:目标明确
诱变,嵌合mRNA和异源启动子,将用于确定机制基础,
其RNA酶L抗性mRNA逃避RNA酶L介导的mRNA周转。目的3:mRNA的单细胞分析
将结合核糖体分析进行表达和蛋白质翻译,以确定RNA酶是否
L介导的mRNA促进RNase L抗性mRNA的翻译。实现这些目标将
确定对RNase L驱动的mRNA周转具有抗性的mRNA的宽度,通过以下方式确定机制:
这些mRNA逃避了RNase L介导的mRNA周转,并提供了一种新的机制,
在先天免疫反应中调节抗病毒基因的表达。
!
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James M Burke其他文献
James M Burke的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James M Burke', 18)}}的其他基金
Understanding the OAS/RNase L pathway during pathogenic viral infections
了解病原性病毒感染期间的 OAS/RNase L 途径
- 批准号:
10714902 - 财政年份:2023
- 资助金额:
$ 6.16万 - 项目类别:
Determining the specificity and biological functions of widespread host mRNA degradation by RNase L
确定 RNase L 广泛降解宿主 mRNA 的特异性和生物学功能
- 批准号:
10116269 - 财政年份:2019
- 资助金额:
$ 6.16万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 6.16万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 6.16万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 6.16万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 6.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 6.16万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 6.16万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 6.16万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 6.16万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 6.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 6.16万 - 项目类别: